# Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

> **NCT01837095** · PHASE1 · COMPLETED · sponsor: **Polyphor Ltd.** · enrollment: 54 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** POL6326

## Key facts

- **NCT ID:** NCT01837095
- **Lead sponsor:** Polyphor Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2018-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01837095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01837095, "Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01837095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*